Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03417141 · ClinicalTrials.gov registry record · Phase 2
Valchlor in the Treatment of Lichen Planopilaris
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT03417141: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT03417141 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03417141, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the potential effectiveness of once daily application of Valchlor in decreasing disease activity in patients with Lichen Planopilaris. The primary measurement of efficacy will be with the Lichen Planopilaris Activity Index (LPPAI) before and after 6 months of treatment. Secondary measures of efficacy will be the mean follicular density, Physician Global assessment (PGA) score, and the Dermatology Quality of Life Index (DQLI) score before and after six months of therapy.
Interventions
- DRUG Mechlorethamine 0.016% Top Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-04-01 |
| Est. Completion | 2019-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03417141
The ClinicalTrials.gov registry entry for NCT03417141 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mechlorethamine 0.016% Top Gel is the first listed.
NCT03417141 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03417141 about?
NCT03417141 is a clinical study titled "Valchlor in the Treatment of Lichen Planopilaris". The primary objective of this study is to assess the potential effectiveness of once daily application of Valchlor in decreasing disease activity in patients with Lichen Planopilaris. The primary measurement of efficacy will be with the Lichen Planopilaris Activity Index (LPPAI) before and after 6 m...
What is the current status of trial NCT03417141?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2018-04-01. Estimated completion is 2019-08-30.
What interventions are being tested in trial NCT03417141?
The interventions under investigation include: Mechlorethamine 0.016% Top Gel (DRUG).
Who is sponsoring clinical trial NCT03417141?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.